Liver Cancer

The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.

While radiation therapy may be a common alternative for inoperable hepatocellular carcinoma, two new studies suggest that proton radiation therapy may offer the same benefits as the more traditionally used photon radiation therapy, with less toxicity.

Nearly one-quarter of inoperable intrahepatic cholangiocarcinomas shrank enough to make surgery possible after selective internal radiation was added to chemotherapy, a study shows.
 

Both men and women have seen an increase in liver cancer diagnoses and death over the past nearly 20 years, according to new study findings.
 

For Liver Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.

Frontline treatment with Opdivo improved overall survival and response rates among patients with advanced hepatocellular carcinoma, however, the trial missed its primary endpoint.

As immunotherapies emerge in the treatment of liver cancer, experts examine whether two or more is better than one.

Taking aspirin was found to improve liver function and extend survival among patients with hepatocellular carcinoma – the most common primary liver cancer.

Researchers at Roswell Park Comprehensive Cancer Center found a biomarker that may help to determine which patients with hepatocellular carcinoma will respond to treatment with Nexavar, leading to more individualized treatment options.

A team of researchers examine funding among different cancer types, exposing disparities in cervical, colon, endometrial, liver and bile duct, lung, ovarian and pancreatic cancer.